CEChristoph M. Ernst

Christoph M. Ernst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christoph M. Ernst has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Peschel

    Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen

    7 shared publications
  • Andreas Peschel

    Interfaculty Institute of Microbiology and Infection Medicine, Infection Biology, University of Tübingen, 72076 Tübingen, Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, 72076 Tübingen, Germany

    4 shared publications
  • Cordula Gekeler

    Department of Infection Biology, Interfaculty Institute for Microbiology and Infection Medicine Tübingen (IMIT), Eberhard Karls University Tübingen

    4 shared publications
  • Deborah T. Hung

    Broad Institute of MIT and Harvard, Cambridge, USA

    4 shared publications
  • Sebastian Kuhn

    Department of Infection Biology, Interfaculty Institute for Microbiology and Infection Medicine Tübingen (IMIT), Eberhard Karls University Tübingen

    4 shared publications
  • Abigail L. Manson

    Broad Institute of MIT and Harvard, Cambridge, MA

    3 shared publications

Latest Publications

  • Klebsiella Brain Abscess and Evolution of Heterovirulence in the Urinary Tract

    by Christoph M. Ernst, Lilly K.S. Fischer, Abigail L. Manson, Li Li, Peijun Ma, Melis N. Anahtar, Roby P. Bhattacharyya, Ashlee M. Earl, Anne E. Clatworthy, Deborah T. Hung

  • Open Access

    High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013–2021

    by Janko Sattler, Christoph M. Ernst, Janine Zweigner, Axel Hamprecht

    Carbapenemase-producing Klebsiella pneumoniae (CP-Kp) isolates are a public health concern as they can cause severe hospital-acquired infections that are difficult to treat. It has recently been shown that CP-Kp can take up virulence factors from hypervirulent K. pneumoniae lineages. In this study, 109 clinical CP-Kp isolates from the University Hospital Cologne were examined for the presence of acquired virulence factors using whole-genome sequencing and phenotypic tests, and results were linked to clinical data. The virulence factor iuc was present in 18/109 of the CP-Kp isolates. Other acquired virulence factors, such as ybt , cbt , iro , rmpA/rmpA2 , peg-344 , and hypervirulence-associated capsule types were detected in various combinations among these isolates. The iuc -positive isolates produced OXA-232 ( n = 7), OXA-48 ( n = 6), OXA-48+NDM ( n = 3), NDM, and KPC (each n = 1), and 7/18 isolates were resistant to ceftazidime-avibactam, colistin, and/or cefiderocol. Four isolates carried hybrid plasmids that harbored acquired virulence factors alongside the carbapenemase genes bla NDM-1/5 or bla OXA-48 . In 15/18 patients, iuc -positive CP-Kp were isolated from a clinically manifest infection site. Among these, four patients had osteomyelitis, and four patients died from pneumonia with OXA-232-producing ST231 isolates, three of them as part of an outbreak. In conclusion, acquired virulence factors are frequently detected in various combinations in carbapenemase-producing K. pneumoniae isolates in Germany, warranting continuous monitoring of infections caused by these strains.


  • Open Access

    PplT domain proteins – ubiquitous potential prokaryotic phospholipid translocases

    by Janna N. Hauser, Arnaud Kengmo Tchoupa, Susanne Zabel, Kay Nieselt, Christoph M. Ernst, Christoph J. Slavetinsky, Andreas Peschel

    Flippase proteins exchanging phospholipids between the cytoplasmic membrane leaflets have been identified in Eukaryotes but remained largely unknown in Prokaryotes. Only MprF proteins that synthesize aminoacyl phospholipids in some bacteria have been found to contain a domain that translocates the produced lipids. We show here that this domain, which we named ‘prokaryotic phospholipid translocator’ (PplT), is widespread in Bacteria and Archaea, encoded as a separate protein or fused to different types of enzymes. We also demonstrate that the Escherichia coli PplT protein interacts with many phospholipid-synthetic enzymes and deletion of pplT impaired bacterial growth, which supports its potential role in membrane lipid metabolism. PplT domain proteins may be general prokaryotic lipid flippases with critical roles in cellular homeostasis.


  • Open Access

    Sensitizing Staphylococcus aureus to antibacterial agents by decoding and blocking the lipid flippase MprF

    by Christoph J Slavetinsky, Janna N Hauser, Cordula Gekeler, Jessica Slavetinsky, André Geyer, Alexandra Kraus, Doris Heilingbrunner, Samuel Wagner, Michael Tesar, Bernhard Krismer, et al.

    The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. Multiple peptide resistance factor (MprF) is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to antimicrobial agents and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding of bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin, and it impaired MRSA survival in human phagocytes. Thus, MprF inhibitors are recommended for new antivirulence approaches against MRSA and other bacterial pathogens.


  • Open Access

    Genetic determinants facilitating the evolution of resistance to carbapenem antibiotics

    by Peijun Ma, Lorrie L He, Alejandro Pironti, Hannah H Laibinis, Christoph M Ernst, Abigail L Manson, Roby P Bhattacharyya, Ashlee M Earl, Jonathan Livny, Deborah T Hung

    In this era of rising antibiotic resistance, in contrast to our increasing understanding of mechanisms that cause resistance, our understanding of mechanisms that influence the propensity to evolve resistance remains limited. Here, we identified genetic factors that facilitate the evolution of resistance to carbapenems, the antibiotic of ‘last resort’, in Klebsiella pneumoniae, the major carbapenem-resistant species. In clinical isolates, we found that high-level transposon insertional mutagenesis plays an important role in contributing to high-level resistance frequencies in several major and emerging carbapenem-resistant lineages. A broader spectrum of resistance-conferring mutations for select carbapenems such as ertapenem also enables higher resistance frequencies and, importantly, creates stepping-stones to achieve high-level resistance to all carbapenems. These mutational mechanisms can contribute to the evolution of resistance, in conjunction with the loss of systems that restrict horizontal resistance gene uptake, such as the CRISPR-Cas system. Given the need for greater antibiotic stewardship, these findings argue that in addition to considering the current efficacy of an antibiotic for a clinical isolate in antibiotic selection, considerations of future efficacy are also important. The genetic background of a clinical isolate and the exact antibiotic identity can and should also be considered as they are determinants of a strain's propensity to become resistant. Together, these findings thus provide a molecular framework for understanding acquisition of carbapenem resistance in K. pneumoniae with important implications for diagnosing and treating this important class of pathogens.


  • Open Access

    Sensitizing Staphylococcus aureus to antibacterial host defense by decoding and blocking the lipid flippase MprF

    by Christoph J. Slavetinsky, Janna N. Hauser, Cordula Gekeler, Jessica Slavetinsky, André Geyer, Alexandra Kraus, Doris Heilingbrunner, Samuel Wagner, Michael Tesar, Christopher Weidenmaier, et al.

    The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. MprF is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to both, human antimicrobials and antibiotics and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding into bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin. Moreover, it impaired MRSA survival in human phagocytes, which recommends MprF inhibitors for new anti-MRSA approaches. MprF-directed monoclonal antibodies provide a proof of concept for development of precisely targeted anti-virulence approaches, which block bacterial antimicrobial resistance mechanisms.

  • Author Correction: Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae

    by Christoph M. Ernst, Julian R. Braxton, Carlos A. Rodriguez-Osorio, Anna P. Zagieboylo, Li Li, Alejandro Pironti, Abigail L. Manson, Anil V. Nair, Maura Benson, Kaelyn Cummins, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Top Cited Papers

    Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae

    by Christoph M. Ernst, Julian R. Braxton, Carlos A. Rodriguez-Osorio, Anna P. Zagieboylo, Li Li, Alejandro Pironti, Abigail L. Manson, Anil V. Nair, Maura Benson, Kaelyn Cummins, et al.

    Among the most urgent public health threats is the worldwide emergence of carbapenem-resistant Enterobacteriaceae1,2,3,4, which are resistant to the antibiotic class of ‘last resort’. In the United States and Europe, carbapenem-resistant strains of the Klebsiella pneumoniae ST258 (ref. 5) sequence type are dominant, endemic6,7,8 and associated with high mortality6,9,10. We report the global evolution of pathogenicity in carbapenem-resistant K. pneumoniae, resulting in the repeated convergence of virulence and carbapenem resistance in the United States and Europe, dating back to as early as 2009. We demonstrate that K. pneumoniae can enhance its pathogenicity by adopting two opposing infection programs through easily acquired gain- and loss-of-function mutations. Single-nucleotide polymorphisms in the capsule biosynthesis gene wzc lead to hypercapsule production, which confers phagocytosis resistance, enhanced dissemination and increased mortality in animal models. In contrast, mutations disrupting capsule biosynthesis genes impair capsule production, which enhances epithelial cell invasion, in vitro biofilm formation and persistence in urinary tract infections. These two types of capsule mutants have emerged repeatedly and independently in Europe and the United States, with hypercapsule mutants associated with bloodstream infections and capsule-deficient mutants associated with urinary tract infections. In the latter case, drug-tolerant K. pneumoniae can persist to yield potentially untreatable, persistent infection.


  • Open Access

    MprF-mediated daptomycin resistance

    by Christoph M. Ernst, Andreas Peschel


  • Open Access

    Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance

    by Christoph M. Ernst, Christoph J. Slavetinsky, Sebastian Kuhn, Janna N. Hauser, Mulugeta Nega, Nagendra N. Mishra, Cordula Gekeler, Arnold S. Bayer, Andreas Peschel

    Ever since daptomycin was introduced to the clinic, daptomycin-resistant isolates have been reported. In most cases, the resistant isolates harbor point mutations in MprF, which produces and flips the positively charged phospholipid LysPG. This has led to the assumption that the resistance mechanism relies on the overproduction of LysPG, given that increased LysPG production may lead to increased electrostatic repulsion of positively charged antimicrobial compounds, including daptomycin. Here we show that the resistance mechanism is highly specific and relies on a different process that involves a functional MprF flippase, suggesting that the resistance-conferring mutations may enable the flippase to accommodate daptomycin or an unknown component that is crucial for its activity. Our report provides a new perspective on the mechanism of resistance to a major antibiotic.